Adopting zanubrutinib for the treatment of chronic lymphocytic leukemia showed improved tolerability and persistence, enhancing patient safety and outcomes.
Margaret Krackeler, MD
Advertisement
Margaret Krackeler, MD, is a hematologist/oncologist at Kaiser Permanente of Northern California.
Articles by Margaret Krackeler, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Trulicity, Botox Headline Drugs Included in the Third Cycle of Medicare Price Negotiations
2
CLL Breakthrough: 100% Efficacy Reported for VenR Retreatment
3
New Dermatologic Therapies Make Waves at Maui Derm 2026
4
AAP Breaks With CDC, Maintains Broader 2026 Childhood and Adolescent Vaccine Schedule
5
